| Lower grade gliomas G Youssef, JJ Miller Current neurology and neuroscience reports 20, 1-9, 2020 | 98 | 2020 |
| RANO 2.0: update to the response assessment in neuro-oncology criteria for high-and low-grade gliomas in adults PY Wen, M van den Bent, G Youssef, TF Cloughesy, BM Ellingson, ... Journal of Clinical Oncology 41 (33), 5187-5199, 2023 | 59* | 2023 |
| GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory Y Rivera-Molina, H Jiang, J Fueyo, T Nguyen, DH Shin, G Youssef, X Fan, ... Neuro-Oncology Advances 1 (1), vdz009, 2019 | 31 | 2019 |
| Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models M Datta, S Chatterjee, EM Perez, S Gritsch, S Roberge, M Duquette, ... Proceedings of the National Academy of Sciences 120 (6), e2219199120, 2023 | 24 | 2023 |
| Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival BM Ellingson, PY Wen, SM Chang, M van den Bent, MA Vogelbaum, G Li, ... Neuro-oncology 25 (6), 1017-1028, 2023 | 22 | 2023 |
| Ipilimumab: an investigational immunotherapy for glioblastoma G Youssef, J Dietrich Expert Opinion on Investigational Drugs 29 (11), 1187-1193, 2020 | 22 | 2020 |
| Evaluation of standard response assessment in neuro-oncology, modified response assessment in neuro-oncology, and immunotherapy response assessment in neuro-oncology in newly … G Youssef, R Rahman, C Bay, W Wang, MJ Lim-Fat, O Arnaout, WL Bi, ... Journal of Clinical Oncology 41 (17), 3160-3171, 2023 | 21 | 2023 |
| Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making MJ Lim-Fat, GC Youssef, M Touat, JB Iorgulescu, S Whorral, M Allen, ... Neuro-oncology 24 (7), 1140-1149, 2022 | 20 | 2022 |
| Pattern reversal visual evoked potentials in adults: variability with age R Sawaya, H Sawaya, G Youssef Clinical and investigative medicine 40 (6), E252-E259, 2017 | 17 | 2017 |
| Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity JA Dean, SK Tanguturi, D Cagney, KY Shin, G Youssef, A Aizer, ... Neuro-oncology 25 (6), 1100-1112, 2023 | 7 | 2023 |
| Medical and neurological management of brain tumor complications G Youssef, PY Wen Current Neurology and Neuroscience Reports 21, 1-14, 2021 | 7 | 2021 |
| Updated response assessment in neuro-oncology (RANO) for gliomas G Youssef, PY Wen Current Neurology and Neuroscience Reports 24 (2), 17-25, 2024 | 4 | 2024 |
| Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma DD Shi, GC Youssef, AH Nassar, MJ Lim-Fat, KL Ligon, PY Wen, ... Neuro-oncology 24 (11), 2005-2007, 2022 | 4 | 2022 |
| Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence SM Christ, G Youssef, SK Tanguturi, D Cagney, D Shi, ... Clinical and Translational Radiation Oncology 44, 100697, 2024 | 3 | 2024 |
| Clinical and genomic predictors of adverse events in newly diagnosed glioblastoma MJ Lim-Fat, JB Iorgulescu, R Rahman, V Bhave, A Muzikansky, ... Clinical Cancer Research 30 (7), 1327-1337, 2024 | 2 | 2024 |
| Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression D Deng, L Hammoudeh, G Youssef, YH Chen, KY Shin, MJ Lim-Fat, ... Neuro-Oncology Advances 5 (1), vdad083, 2023 | 2 | 2023 |
| Comparison of survival outcomes of patients with newly diagnosed glioblastoma treated with standard chemoradiation in and outside of clinical trials. R Rahman, G Youssef, S Ventz, R Redd, J McDunn, W Louv, ... Journal of Clinical Oncology 40 (16_suppl), 2051-2051, 2022 | 1 | 2022 |
| BIOM-44. Genomic predictors of adverse events in newly diagnosed IDH-wildtype glioblastoma M Jane Lim-Fat, R Rahman, A Muzikansky, E Woodward, S Whorral, ... Neuro-Oncology 22 (Supplement_2), ii11-ii11, 2020 | 1 | 2020 |
| Management of glioma patients during the coronavirus disease 2019 pandemic G Youssef, PY Wen Glioma 3 (2), 31-33, 2020 | 1 | 2020 |
| EXTH-27. Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator gitrl Y Rivera-Molina, J Fueyo, H Jiang, T Nguyen, D Ho Shin, G Youssef, ... Neuro-Oncology 21 (Supplement_6), vi87-vi87, 2019 | 1 | 2019 |
